BDNF, interleukin-6, and salivary cortisol levels in depressed patients treated with desvenlafaxine

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 48, Issue , 2014, Pages 86-91

  Ninan, Philip T ^a,b   Shelton, Richard C ^c   Bao, Weihang ^b   Guico Pabia, Christine J ^b  

^a EAST CAROLINA UNIVERSITY   (United States)

^b PFIZER INC   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Brain derived neurotrophic factor; Depression; Desvenlafaxine; Interleukin 6; Salivary cortisol

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; DESVENLAFAXINE; HYDROCORTISONE; INTERLEUKIN 6; PLACEBO;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE MARKER; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; REMISSION; SALIVA LEVEL; TREATMENT DURATION; TREATMENT RESPONSE;

17-ITEM HAMILTON RATING SCALE FOR DEPRESSION; BDNF; BRAIN-DERIVED NEUROTROPHIC FACTOR; DEPRESSION; DESVENLAFAXINE; HAM-D(17); IL; INTERLEUKIN; INTERLEUKIN 6; MADRS; MAJOR DEPRESSIVE DISORDER; MDD; MONTGOMERY-ÅSBERG DEPRESSION RATING SCALE; NERVE GROWTH FACTOR; NEUROTROPHIN; NGF; NT; RS; SALIVARY CORTISOL; SDS; SHEEHAN DISABILITY SCALE; SPEARMAN CORRELATION COEFFICIENT;

ADULT; AGED; ANTIDEPRESSIVE AGENTS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CYCLOHEXANOLS; DEPRESSION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYDROCORTISONE; INTERLEUKIN-6; MALE; MIDDLE AGED; OUTPATIENTS; PSYCHIATRIC STATUS RATING SCALES; SALIVA; SEVERITY OF ILLNESS INDEX; STATISTICS AS TOPIC; YOUNG ADULT;

EID: 84885752347     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2013.09.016     Document Type: Article

References (34)

1. American Psychiatric Association Diagnostic and statistical manual of mental disorders, text revision: DSM-IV-TR 2000, American Psychiatric Publishing, Washington, DC.
2. Aubry J.M., Jermann F., Gex-Fabry M., Bockhorn L., Van der Linden M., Gervasoni N., et al. The cortisol awakening response in patients remitted from depression. J Psychiatr Res 2010, 44:1199-1204.
3. Bob P., Raboch J., Maes M., Susta M., Pavlat J., Jasova D., et al. Depression, traumatic stress and interleukin-6. J Affect Disord 2010, 120:231-234.
4. Bocchio-Chiavetto L., Bagnardi V., Zanardini R., Molteni R., Nielsen M.G., Placentino A., et al. Serum and plasma BDNF levels in major depression: a replication study and meta-analyses. World J Biol Psychiatry 2010, 11:763-773.
5. Brunoni A.R., Lopes M., Fregni F. A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression. Int J Neuropsychopharmacol 2008, 11:1169-1180.
6. Castren E., Rantamaki T. The role of BDNF and its receptors in depression and antidepressant drug action: reactivation of developmental plasticity. Dev Neurobiol 2010, 70:289-297.
7. Cohen H.J., Pieper C.F., Harris T., Rao K.M., Currie M.S. The association of plasma IL-6 levels with functional disability in community-dwelling elderly. J Gerontol A Biol Sci Med Sci 1997, 52:M201-M208.
8. Dell'Osso L., Del D.A., Veltri A., Bianchi C., Roncaglia I., Carlini M., et al. Associations between brain-derived neurotrophic factor plasma levels and severity of the illness, recurrence and symptoms in depressed patients. Neuropsychobiology 2010, 62:207-212.
9. Deuschle M., Gilles M., Scharnholz B., Lederbogen F., Lang U.E., Hellweg R. Changes of serum concentrations of brain-derived neurotrophic factor (BDNF) during treatment with venlafaxine and mirtazapine: role of medication and response to treatment. Pharmacopsychiatry 2013, 46:54-58.
10. Dowlati Y., Herrmann N., Swardfager W., Liu H., Sham L., Reim E.K., et al. A meta-analysis of cytokines in major depression. Biol Psychiatry 2010, 67:446-457.
11. Dunlop B.W., Reddy S., Yang L., Lubaczewski S., Focht K., Guico-Pabia C.J. Symptomatic and functional improvement in employed depressed patients: a double-blind clinical trial of desvenlafaxine versus placebo. J Clin Psychopharmacol 2011, 31:569-576.
12. Gass P., Hellweg R. Peripheral brain-derived neurotrophic factor (BDNF) as a biomarker for affective disorders?. Int J Neuropsychopharmacol 2010, 13:1-4.
13. Gex-Fabry M., Jermann F., Kosel M., Rossier M.F., Van der Linden M., Bertschy G., et al. Salivary cortisol profiles in patients remitted from recurrent depression: one-year follow-up of a mindfulness-based cognitive therapy trial. J Psychiatr Res 2012, 46:80-86.
14. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960, 23:56-62.
15. Hashimoto K. Brain-derived neurotrophic factor as a biomarker for mood disorders: an historical overview and future directions. Psychiatry Clin Neurosci 2010, 64:341-357.
16. Hellhammer D.H., Wust S., Kudielka B.M. Salivary cortisol as a biomarker in stress research. Psychoneuroendocrinology 2009, 34:163-171.
17. Hellweg R., Ziegenhorn A., Heuser I., Deuschle M. Serum concentrations of nerve growth factor and brain-derived neurotrophic factor in depressed patients before and after antidepressant treatment. Pharmacopsychiatry 2008, 41:66-71.
18. Hinkelmann K., Moritz S., Botzenhardt J., Riedesel K., Wiedemann K., Kellner M., et al. Cognitive impairment in major depression: association with salivary cortisol. Biol Psychiatry 2009, 66:879-885.
19. Hu Y., Yu X., Yang F., Si T., Wang W., Tan Y., et al. The level of serum brain-derived neurotrophic factor is associated with the therapeutic efficacy of modified electroconvulsive therapy in Chinese patients with depression. J ECT 2010, 26:121-125.
20. Jevtovic S., Karlovic D., Mihaljevic-Peles A., Seric V., Vrkic N., Jaksic N. Serum brain-derived neurotrophic factor (BDNF): the severity and symptomatic dimensions of depression. Psychiatr Danub 2011, 23:363-369.
21. Knorr U., Vinberg M., Kessing L.V., Wetterslev J. Salivary cortisol in depressed patients versus control persons: a systematic review and meta-analysis. Psychoneuroendocrinology 2010, 35:1275-1286.
22. Knorr U., Vinberg M., Gether U., Winkel P., Gluud C., Wetterslev J., et al. The effect of escitalopram versus placebo on perceived stress and salivary cortisol in healthy first-degree relatives of patients with depression-a randomised trial. Psychiatry Res 2012, 200:354-360.
23. Matrisciano F., Bonaccorso S., Ricciardi A., Scaccianoce S., Panaccione I., Wang L., et al. Changes in BDNF serum levels in patients with major depression disorder (MDD) after 6months treatment with sertraline, escitalopram, or venlafaxine. J Psychiatr Res 2009, 43:247-254.
24. Molendijk M.L., Bus B.A., Spinhoven P., Penninx B.W., Kenis G., Prickaerts J., et al. Serum levels of brain-derived neurotrophic factor in major depressive disorder: state-trait issues, clinical features and pharmacological treatment. Mol Psychiatry 2011, 16:1088-1095.
25. Montgomery S.A., Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979, 134:382-389.
26. R&D Systems Human BDNF quantikine ELISA kit Available at:, [Accessed July 2, 2013]. http://www.rndsystems.com/Products/dbd00/.
27. R&D Systems Human IL-6 quantikine ELISA kit Available at:, [Accessed July 2, 2013]. http://www.rndsystems.com/Products/D6050.
28. Sheehan D.V. Sheehan disability scale. Handbook of psychiatric measures 2000, 113-115. American Psychiatric Association, Washington, DC. A.J. Rush, H.A. Pincus, M.B. First (Eds.).
29. Tadic A., Wagner S., Schlicht K.F., Peetz D., Borysenko L., Dreimuller N., et al. The early non-increase of serum BDNF predicts failure of antidepressant treatment in patients with major depression: a pilot study. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35:415-420.
30. Wolkowitz O.M., Wolf J., Shelly W., Rosser R., Burke H.M., Lerner G.K., et al. Serum BDNF levels before treatment predict SSRI response in depression. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35:1623-1630.
31. World Health Organization The global burden of disease. 2004 update. World Health Organization Available at:, [Accessed November 9, 2012]. http://www.who.int/healthinfo/global_burden_disease/2004_report_update/en/index.html.
32. World Health Organization Depression Available at:, [Accessed June 11, 2012]. http://www.who.int/mental_health/management/depression/definition/en/print.html.
33. Zhang X.Y., Xiu M.H., Chen D.C., Yang F.D., Wu G.Y., Lu L., et al. Nicotine dependence and serum BDNF levels in male patients with schizophrenia. Psychopharmacology (Berl) 2010, 212:301-307.
34. Ziegenhorn A.A., Schulte-Herbruggen O., Danker-Hopfe H., Malbranc M., Hartung H.D., Anders D., et al. Serum neurotrophins-a study on the time course and influencing factors in a large old age sample. Neurobiol Aging 2007, 28:1436-1445.